Merkel Cell Carcinoma — Trials

Merkel Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

133 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 51
Recruiting: 25
Ph III recruiting: 0
Growth YoY: —
Industry share: 25%
Top sponsor: H. Lee Moffitt Cancer Center and Research Institute
Termination share: 45.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (27)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03089658	Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)	approved for marketing	—	—	Merck KGaA, Darmstadt, GermanyINDUSTRY	1	Oct 9, 2019	clinicaltrials

Data updated 22 days agoSource updated Oct 9, 2019source: clinicaltrials